Par Drugs and Chemicals Limited

NSE:PAR.NS

302.6 (INR) • At close November 5, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 346.569226.056228.192239.991258.873229.347238.379229.327248.18235.065212.064169.155195.948164.834153.408162.719141.336141.336133.686133.686145.557145.557107.309107.309124.308124.308
Cost of Revenue 143.2674.86199.264101.517110.239116.247349.154102.592104.247108.057304.58464.91968.12861.006206.92761.47752.98452.98459.92359.92361.60361.60342.0442.0454.06754.067
Gross Profit 203.309151.195128.928138.474148.634113.1-110.775126.735143.933127.008-92.52104.236127.82103.828-53.519101.24288.35388.35373.76373.76383.95583.95565.26865.26870.24170.241
Gross Profit Ratio 0.5870.6690.5650.5770.5740.493-0.4650.5530.580.54-0.4360.6160.6520.63-0.3490.6220.6250.6250.5520.5520.5770.5770.6080.6080.5650.565
Reseach & Development Expenses 0000002.7750001.2170000.9880000.3330.333000.2720.27200
General & Administrative Expenses 00000000000000000000000000
Selling & Marketing Expenses 00000000000000000000000000
SG&A 98.30812.61776.90894.83783.48780.0915.57513.39374.54680.54669.10258.37777.76753.70812.0210.3858.698.6910.36810.36810.210.27.9167.91610.55910.559
Other Expenses 0117.883-0.482.2910.4910.12100.3770.15897.419-125.8850.5180.2770.374-0.3460.3110000000000
Operating Expenses 98.308117.88376.90894.83783.48780.09-151.905101.85394.01397.419-125.88576.38195.72270.594-88.9668.43456.39656.39652.95552.95571.33571.33556.36456.36454.99954.999
Operating Income 105.00133.31252.0243.63765.14733.0145.34924.88250.07931.12336.45428.37332.37533.60736.33333.11931.68531.68520.82420.82412.61212.6129.7199.71915.91215.912
Operating Income Ratio 0.3030.1470.2280.1820.2520.1440.190.1090.2020.1320.1720.1680.1650.2040.2370.2040.2240.2240.1560.1560.0870.0870.0910.0910.1280.128
Total Other Income Expenses Net 9.8680.538-0.9312.0950.224-0.0360.0450.081-0.3-0.467-0.171-0.99-2.282-0.33417.741-0.49-1.406-1.406-1.389-1.389-2.088-2.088-3.727-3.727-5.72-5.72
Income Before Tax 114.86933.8551.08945.73265.37132.97445.39424.96449.77930.65636.28327.38330.09333.27354.07432.62930.27930.27919.43519.43510.52410.5245.9915.99110.19210.192
Income Before Tax Ratio 0.3310.150.2240.1910.2530.1440.190.1090.2010.130.1710.1620.1540.2020.3520.2010.2140.2140.1450.1450.0720.0720.0560.0560.0820.082
Income Tax Expense 28.918.51913.89511.5116.4538.29910.9246.28312.5287.71512.0416.237.898.729.90211.7984.7254.7253.5533.5532.5812.5813.9033.9033.3543.354
Net Income 85.95825.33137.19434.22248.91824.67534.4718.6837.25122.9424.24221.15322.20324.55344.17220.83125.55525.55515.88215.8827.9437.9432.0882.0886.8396.839
Net Income Ratio 0.2480.1120.1630.1430.1890.1080.1450.0810.150.0980.1140.1250.1130.1490.2880.1280.1810.1810.1190.1190.0550.0550.0190.0190.0550.055
EPS 6.992.063.022.783.982.012.81.523.031.861.971.721.823.593.392.082.081.291.290.650.650.170.171.271.27
EPS Diluted 6.992.063.022.783.982.012.81.523.031.861.971.721.823.593.392.082.081.291.290.650.650.170.171.271.27
EBITDA 123.94943.08660.93952.2973.62541.32151.17132.68559.20638.42445.12536.1240.72441.65243.59739.32839.04639.04621.15421.15426.08926.08918.27418.27422.54222.542
EBITDA Ratio 0.3580.1910.2670.2180.2840.180.2150.1430.2390.1630.2130.2140.2080.2530.2840.2420.2760.2760.1580.1580.1790.1790.170.170.1810.181